Statements (53)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:physicist
|
| gptkbp:bfsLayer |
5
|
| gptkbp:bfsParent |
gptkb:Genzyme_Genetics
|
| gptkbp:activities |
replaces the missing enzyme alpha-L-iduronidase
|
| gptkbp:approves |
gptkb:2003
gptkb:FDA |
| gptkbp:availability |
prescription only
|
| gptkbp:clinical_trial |
improved quality of life
Phase III long-term treatment improved walking ability reduced organ size |
| gptkbp:contraindication |
hypersensitivity to laronidase
|
| gptkbp:developed_by |
gptkb:Sanofi_Genzyme
|
| gptkbp:dosage_form |
solution for infusion
|
| gptkbp:duration |
every week
|
| gptkbp:education |
important for understanding treatment
|
| https://www.w3.org/2000/01/rdf-schema#label |
Aldurazyme
|
| gptkbp:indication |
severe forms of MPSI
|
| gptkbp:ingredients |
laronidase
|
| gptkbp:interacts_with |
no significant interactions reported
|
| gptkbp:is_a_route_for |
primarily renal
|
| gptkbp:is_available_on |
gptkb:brand
|
| gptkbp:is_monitored_by |
renal function
liver function infusion reactions |
| gptkbp:is_used_for |
treatment of mucopolysaccharidosis I (MPSI)
|
| gptkbp:manager |
intravenous infusion
|
| gptkbp:marketed_as |
gptkb:legislation
gptkb:United_States |
| gptkbp:packaging |
vials
|
| gptkbp:pharmacokinetics |
elimination half-life of approximately 2.5 hours
increases the levels of glycosaminoglycans in urine |
| gptkbp:population |
children and adults
|
| gptkbp:price |
high
|
| gptkbp:provides_information_on |
included in treatment protocols for MPSI
|
| gptkbp:regulatory_compliance |
approved for use in multiple countries
|
| gptkbp:research_focus |
gene therapy alternatives
|
| gptkbp:side_effect |
fatigue
headache nausea abdominal pain fever urticaria rash chills anaphylaxis infusion reactions |
| gptkbp:social_structure |
glycoprotein
|
| gptkbp:storage |
refrigerated at 2-8° C
|
| gptkbp:supply_chain |
cold chain required
|
| gptkbp:type_of_care |
important for treatment efficacy
|
| gptkbp:weight |
approximately 76 k Da
|